Kumpanart Soontornvipart

Kumpanart Soontornvipart

Auto-generated profile, based on publicly available information

Kumpanart Soontornvipart

Department of Veterinary Surgery Faculty of Veterinary Science Chulalongkorn University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
CPChanthawat Patikorn
Chanthawat Patikorn
ONOsot Nerapusee
Osot Nerapusee
KSKumpanart Soontornvipart
Kumpanart Soontornvipart
KLKanta Lawonyawut
Kanta Lawonyawut
KMKachapong Musikpodok
Kachapong Musikpodok
PAPuree Anantachoti
Puree Anantachoti
Introduction: Canine osteoarthritis (OA) is a degenerative disease with chronic inflammation of internal and external joint structures in dogs.Cannabisspp. contains cannabidiol (CBD), a substance known for various potential indications, such as pain relief and anti-inflammatory in various types of animals, including dogs with OA. As CBD is increasingly in the spotlight for medical use, we aimed to perform a systematic review and meta-analysis to evaluate the efficacy and safety of CBD in treating canine OA.Methods: We searched PubMed, Embase, Scopus, and CAB Direct for animal intervention studies investigating the effects of CBD for canine OA from database inception until February 28, 2023. Study characteristics and findings were summarized. A risk of bias in the included studies was assessed. Meta-analyses were performed using a random-effects model to estimate the effects of CBD on pain scores (0–10), expressed as mean difference (MD) and 95% confidence interval (95% CI). Certainty of evidence was assessed using GRADE.Results: Five articles were included, which investigated the effects of CBD in 117 dogs with OA. All studies were rated as having a high risk of bias. CBD products varied substantially, i.e., oral full-spectrum CBD oil in four studies, and isolated CBD oil and liposomal CBD oil in another study. Treatment duration varied from 4–12 weeks. Meta-analyses of three studies found that, in dogs with OA, treatment with oral full-spectrum CBD oil may reduce pain severity scores (MD; −0.60, 95% CI; −1.51 to 0.31,I2= 45.64%,p = 0.19) and pain interference scores (MD; −1.52, 95% CI; −3.84 to 0.80,I2= 89.59%,p = 0.20) but the certainty of evidence was very low. CBD is generally considered safe and well-tolerated in the short-run, with few mild adverse events observed, such as vomiting and asymptomatic increase in alkaline phosphatase level.Conclusion: CBD is considered safe for treating canine OA. CBD may reduce pain scores, but the evidence is very uncertain to conclude its clinical efficacy. High-quality clinical trials are needed to further evaluate the roles of CBD in canine OA.

27 May 2023 in Veterinary World
Verified
Journal Article
Open access
KJKotchapol Jaturanratsamee
Kotchapol Jaturanratsamee
NCNan Choisunirachon
Nan Choisunirachon
KSKumpanart Soontornvipart
Kumpanart Soontornvipart
DDDamri Darawiroj
Damri Darawiroj
NSNaparee Srisowanna
Naparee Srisowanna
CTChutimon Thanaboonnipat
Chutimon Thanaboonnipat
Background and Aim: Chronic kidney disease (CKD) is one of the most important diseases in cats. This study aimed to compare the ultrasonographic kidney length-to-abdominal aortic diameter (K/AO) ratio between healthy and CKD cats and investigate the correlation between K/AO and blood results. Materials and Methods: Fifteen healthy cats and 15 CKD cats were included in this clinically prospective study. All cats were evaluated for radiographic and ultrasonographic K, radiographic K-to-second lumbar length ratio (K/L2), and K/AO, indirect systolic blood pressure and plasma creatinine (Cr), blood urea nitrogen (BUN), and symmetric dimethyl arginine (SDMA). Results: The radiographic and ultrasonographic kidney lengths of CKD were significantly shorter than those of healthy cats (p < 0.05 and p < 0.05, respectively). The average K/L2 and K/AO were significantly lower in CKD than in healthy cats (p < 0.01 and p < 0.001, respectively). The K/AO had a strong negative correlation with plasma Cr (r = −0.7682, p < 0.0001), BUN (r = −0.6175, p < 0.001), and SDMA (r = −0.589, p < 0.001). However, K/L2 had a moderate negative correlation with plasma Cr (r = −0.5866, p < 0.001), BUN (r = −0.4884, p < 0.01), and SDMA (r = −0.5404, p < 0.01). The optimal cutoff value of K/AO (<10.71) had higher sensitivity and specificity than K/L2 for identifying feline CKD. Conclusion: Kidney length-to-abdominal aortic diameter could be a better and more promising parameter than the K/L2 ratio for evaluating kidney size in cats with CKD. Keywords: cats, chronic kidney disease, kidney length-to-abdominal aortic diameter, renal length, ultrasonography.

1 January 2021 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
KKKanokporn Kanthavichit
Kanokporn Kanthavichit
AKAuraiwan Klaengkaew
Auraiwan Klaengkaew
CTChutimon Thanaboonnipat
Chutimon Thanaboonnipat
DDDamri Darawiroj
Damri Darawiroj
KSKumpanart Soontornvipart
Kumpanart Soontornvipart
NCNan Choisunirachon
Nan Choisunirachon
Kanthavichit K, et al. J Vet Sci. 2021 Jul;22(4):e58. https://doi.org/10.4142/jvs.2021.22.e58


27 October 2026 in Veterinary Medicine and Science
Verified
Journal Article
Open access
KSKumpanart Soontornvipart
Kumpanart Soontornvipart
RSRatthanan Sathienbumrungkit
Ratthanan Sathienbumrungkit
Objective: This research evaluated the chondroprotective efficacy of PCSO‐524 in dogs with osteoarthritis (OA) secondary to medial patellar luxation (MPL) using ultrasonography − a non‐invasive technique recommended for early OA detection. Materials and Methods: Animals: 25 dogs total (21 with MPL grade II, 50 stifle joints evaluated) divided into three groups, including control group: 10 dogs receiving placebo, treatment group: 11 dogs receiving PCSO‐524 (50 mg daily) and normal group: 4 healthy dogs (reference) Duration: 16 weeks Evaluations: Lameness scores, blood profiles, ultrasonographic findings, radiographic assessments and owner questionnaires at baseline, weeks 2, 4, 8, 12 and 16. Results: The treatment group showed significant improvement in lameness scores within 8 weeks. The cartilage lesions improved within 4 weeks of PCSO‐524 administration. Synovial fluid scores decreased significantly by week 4 in the treatment group. Radiographic OA scores improved mildly at 12 weeks in the treatment group versus progression in the control group. Owners observed better gait and quality of life by week 2. No adverse effects on blood chemistry or organ function. Conclusion: PCSO‐524 demonstrates effective cartilage protection in dogs with OA secondary to MPL, with improvements in clinical signs, ultrasonographic findings and radiographic outcomes. For dogs that cannot undergo surgical correction, PCSO‐524 supplementation combined with quadriceps muscle training and environmental management is recommended for improved quality of life.

25 April 2026 in Veterinary World
Verified
Journal Article
Open access
APAujchariyaporn Phongphuwanan
Aujchariyaporn Phongphuwanan
STSirinun Pisamai Tabtieang
Sirinun Pisamai Tabtieang
CTChutimon Thanaboonnipat
Chutimon Thanaboonnipat
TCTeerapol Chinkangsadarn
Teerapol Chinkangsadarn
TTThita Taecholan
Thita Taecholan
KSKumpanart Soontornvipart
Kumpanart Soontornvipart
Background and Aim: Obesity and osteoarthritis (OA) frequently coexist in dogs and synergistically impair mobility, muscle integrity, and quality of life (QoL). Conventional management using nonsteroidal anti-inflammatory drugs may be limited by adverse effects, particularly in overweight and geriatric patients. Bedinvetmab, a canine anti–nerve growth factor monoclonal antibody, offers targeted analgesia with a favorable safety profile. This study aimed to evaluate the effects of bedinvetmab on daily physical activity, chronic pain, and body composition in obese dogs with OA. Materials and Methods: A 56-day prospective, randomized, double-blind, placebo-controlled clinical trial was conducted in 28 client-owned obese dogs diagnosed with OA. Dogs were allocated to receive either bedinvetmab (1 mg/kg) or placebo via subcutaneous injection on Days 0 and 28. Daily activity was quantified as the mean accelerometer-derived activity count per day (MAC/day). Pain and QoL were assessed using the Canine Brief Pain Inventory. Body composition parameters included body weight, body condition score, abdominal girth, thigh girth, and estimated body fat percentage. Data were analyzed using linear mixed-effects models, repeated-measures analysis of variance, and correlation analysis, with p < 0.05 considered significant. Results: The treatment group demonstrated significant improvements in both objective and subjective outcomes. MAC/day increased significantly over time, with a 25.6% rise from baseline by Day 56 (p = 0.032). Concurrently, total pain scores decreased significantly, with a mean reduction of 1.95 points (p < 0.001). A moderate negative correlation was observed between MAC/day and pain scores (r = −0.519, p < 0.001), indicating that reduced pain was associated with increased activity. Body weight did not change significantly; however, the treatment group exhibited a significant reduction in estimated body fat percentage and preservation of thigh muscle mass compared with placebo. No adverse effects were reported. Conclusion: Bedinvetmab is a safe and effective therapeutic option for managing OA-related pain in obese dogs, leading to improved mobility and QoL. Importantly, it contributes to favorable body composition changes, particularly muscle preservation, despite minimal weight loss. These findings support its integration into multimodal OA management strategies, especially in high-risk populations where conventional therapies are limited. Keywords: accelerometer, activity monitoring, bedinvetmab, body composition, canine osteoarthritis, chronic pain, muscle preservation, obesity.